Glossary
| Acronym | Definition | placeholder | placeholder |
|---|---|---|---|
| AI | Artificial intelligence | placeholder |
placeholder |
| AIDS | Acquired immunodeficiency syndrome | placeholder |
placeholder |
| AMR | Antimicrobial resistance | placeholder |
placeholder |
| ARV | Antiretroviral | placeholder |
placeholder |
| BARDA | Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services | placeholder |
placeholder |
| CDC | Centers for Disease Control and Prevention | placeholder |
placeholder |
| DEI | Diversity, equity and inclusion | placeholder |
placeholder |
| DR-TB | Drug-resistant tuberculosis | placeholder |
placeholder |
| ECDC | European Centre for Disease Prevention and Control | placeholder |
placeholder |
| EH&S | Environmental Health & Safety | placeholder |
placeholder |
| EMA | European Medicines Agency | placeholder |
placeholder |
| EMEA | Europe, Middle East and Africa | placeholder |
placeholder |
| EML | WHO Model List of Essential Medicines | placeholder |
placeholder |
| ESG | Environmental, social and governance | placeholder |
placeholder |
| EUA | Emergency Use Authorization | placeholder |
placeholder |
| EUL | Emergency Use Listing |
placeholder |
placeholder |
| ExPEC | Extraintestinal pathogenic Escherichia coli | placeholder |
placeholder |
| FDA | U.S. Food and Drug Administration | placeholder |
placeholder |
| GCI | Global Community Impact | placeholder |
placeholder |
| GBP | Global Brand Protection | placeholder |
placeholder |
| GHG | Greenhouse gas or gases | placeholder |
placeholder |
| GPH | Global Public Health | placeholder |
placeholder |
| HCP | Healthcare professional | placeholder |
placeholder |
| HIV | Human immunodeficiency virus | placeholder |
placeholder |
| IP | Intellectual Property | placeholder |
placeholder |
| JJBC | Johnson & Johnson Bioethics Committee | placeholder |
placeholder |
| JJDC | Johnson & Johnson Innovation—JJDC, Inc. | placeholder |
placeholder |
| J&J MedTech | Johnson & Johnson MedTech | placeholder |
placeholder |
| JLABS | Johnson & Johnson Innovation—JLABS | placeholder |
placeholder |
| LAI | Long-acting injectable | placeholder |
placeholder |
| LMICs | Low- and middle-income countries | placeholder |
placeholder |
| MDR-TB | Multidrug-resistant tuberculosis | placeholder |
placeholder |
| NGO | Non-governmental organization | placeholder |
placeholder |
| NIH | National Institutes of Health | placeholder |
placeholder |
| OCMO | The Johnson & Johnson Office of the Chief Medical Officer | placeholder |
placeholder |
| PAH | Pulmonary arterial hypertension | placeholder |
placeholder |
| PPE | Personal protective equipment | placeholder |
placeholder |
| PTA | Priority Topics Assessment | placeholder |
placeholder |
| RLS | Resource-limited settings | placeholder |
placeholder |
| RNA | Ribonucleic acid | placeholder |
placeholder |
| RSV | Respiratory syncytial virus | placeholder |
placeholder |
| RWD | Real-world data | placeholder |
placeholder |
| SDG | Sustainable Development Goal (of the United Nations) | placeholder |
placeholder |
| SEC | U.S. Securities and Exchange Commission | placeholder |
placeholder |
| SSP | Supplier Sustainability Program | placeholder |
placeholder |
| STEM | Science, Technology, Engineering, and Mathematics | placeholder |
placeholder |
| STH | Soil-transmitted helminthiasis (or intestinal parasites) |
placeholder |
placeholder |
| TB | Tuberculosis | placeholder |
placeholder |
| VR | Virtual reality | placeholder |
placeholder |
| WHO | World Health Organization | placeholder |
placeholder |
